Myocardial infarct artery patency and reocclusion rates after treatment with duteplase at the dose used in the International Study of Infarct Survival-3. Burroughs Wellcome Study Group.

Kalbfleisch, J M; Kurnik, P B; Thadani, U; DeWood, M A; Kent, R; Magorien, R D; Jain, A C; Spaccavento, L J; Morris, D L; Taylor, G J

Kalbfleisch, J M; Kurnik, P B; Thadani, U; DeWood, M A; Kent, R; Magorien, R D; Jain, A C; Spaccavento, L J; Morris, D L; Taylor, G J.

Affiliation

Kalbfleisch JM; Cardiology of Tulsa, Inc., Oklahoma 74136.

Am J Cardiol ; 71(5): 386-92, 1993 Feb 15.

Article in En | MEDLINE | ID: mdl-8430624

Subject(s)

Coronary Vessels/drug effects; Myocardial Infarction/drug therapy; Tissue Plasminogen Activator/administration & dosage; Vascular Patency/drug effects; Coronary Angiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction/diagnostic imaging; Myocardial Infarction/mortality; Recombinant Proteins/administration & dosage; Recombinant Proteins/therapeutic use; Recurrence; Time Factors; Tissue Plasminogen Activator/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Vascular Patency / Tissue Plasminogen Activator / Coronary Vessels / Myocardial Infarction Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Am J Cardiol Year: 1993 Document type: Article

Search on Google

XML

PubMed Links